GLP-1 drugs before anesthesia
Should GLP-1 receptor agonists be continued or withheld before anesthesia? Compare residual gastric-content studies with actual aspiration outcomes, and distinguish elective surgery from endoscopy.
Published studies
Open in feedRecent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.
Showing 7 of 87 · Observational
Recent evidence · past year
-
The Impact of Glucagon-Like Peptide 1 Receptor Agonists Versus Diabetes Mellitus on Endoscopic Procedures: A Case-Control Study From a Large Tertiary Care Health System.
AI summary of the abstract, unverified
- A retrospective case-control study at a large tertiary health system compared GLP1-RA users with matched diabetics off GLP1-RAs undergoing outpatient EGD and/or colonoscopy from 2018 to 2023.
- Cases never held their GLP1-RAs, and the authors also examined a 24-hour preprocedural liquid diet plus bowel preparation as a way to reduce gastric retention risk.
- Gastric food retention was higher in cases than controls (4.7% vs 1%, P=0.03), while inadequate bowel preparation was identical at 16.5% in both groups.
- The authors conclude GLP1-RAs raise gastric food retention independent of diabetes, and that a 24-hour liquid diet with bowel preparation appears to offset that risk.
Original abstract (PubMed)
OBJECTIVES: While glucagon-like peptide 1 receptor agonists (GLP1-RAs) increase the risk of gastric food retention (GFR) and inadequate bowel preparation (IBP), the confounding role of diabetes mellitus is still questioned. Here, we compare the outcomes of endoscopic procedures in patients on GLP1-RAs versus matched diabetics off GLP1-RAs, while also assessing the role of a 24-hour preprocedural liquid diet and bowel preparation in mitigating this risk. METHODS: A retrospective case-control study of patients 18 years or older on GLP1-RAs versus matched diabetics off GLP1-RAs who underwent outpatient EGD and/or colonoscopy between January 2018 and June 2023. The case group never held their GLP1-RAs. Primary outcomes were the risk of GFR and IBP. Secondary outcomes included the rates of aborted procedures, periprocedural aspiration, and the risk of GFR in GLP1-RAs who underwent EGD alone versus EGD + colonoscopy. RESULTS: Our study included 417 EGDs (212 cases vs. 205 controls) and 637 colonoscopies (303 cases vs. 334 controls). There was no significant difference in age, gender, BMI, and preprocedural A1c% between groups. The GFR was significantly higher in the cases compared with controls (4.7% vs. 1%, P =0.03), whereas there was no difference in IBP (16.5% vs. 16.5%, P =1). There was no significant difference in EGD abortion (1.9% vs. 0.5%, P =0.3) or colonoscopy abortion (7.6% vs. 6%, P =0.4) between cases and controls. None of the patients in both groups had periprocedural aspiration or conversion to general anesthesia. Compared with EGD alone (n=105), cases who underwent a concomitant colonoscopy (n=107) had a significantly lower risk of GFR (9.5% vs. 0%, P <0.01). DISCUSSION: GLP1-RAs increase the risk of GFR independent of concomitant diabetes but not the rate of IBP. The absolute procedural risks associated with GLP1-RAs are minimal. A 24-hour liquid diet combined with bowel preparation appears to offset the risk of GFR associated with GLP1-RAs.
-
Glucagon-like Peptide-1 receptor agonist use is associated with decreased risk of periprosthetic joint infection following total knee arthroplasty: A laterality-verified propensity matched comparison.
AI summary of the abstract, unverified
- This retrospective TriNetX database study propensity-matched 1:1 GLP-1 RA users with non-user controls undergoing total knee arthroplasty, tracking outcomes over 2 years.
- The exposure was GLP-1 RA use within the year before TKA, compared with non-users, with laterality assessed to attribute complications to the operated knee.
- PJI was lower in users (1.5% vs. 2.0%; RR 0.74; 95% CI 0.57 to 0.96; P = 0.02), and the difference persisted among diabetic patients (RR 0.68; 95% CI 0.52 to 0.89; P < 0.01).
- Revision, mechanical loosening, periprosthetic fracture, and other mechanical complications did not differ, which the authors interpret as a selective effect against infection.
Original abstract (PubMed)
IntroductionDiabetes and obesity are associated with increased risk of complications following total knee arthroplasty (TKA). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a modality for optimizing weight and glycemic control in the perioperative period. This study aims to compare 2-year postoperative complications between GLP-1 RA users and non-users, using laterality-verified methodology to ensure ipsilateral outcome attribution.MethodsA retrospective query of the TriNetX database identified patients who underwent TKA and used GLP-1 RAs within a 1-year preoperative period. GLP-1 RA patients were 1:1 propensity matched to non-user controls for demographics and confounding comorbidities. Laterality was assessed independently to ensure ipsilateral TKA and corresponding complication. Outcomes analyzed were TKA revision, periprosthetic joint infection (PJI), mechanical loosening, periprosthetic fracture, and other mechanical complications within a 2-year postoperative period. Results were further stratified to isolate outcomes among diabetic patients. Results were reported as risk ratios, 95% confidence intervals, and P values.ResultsGLP-1 RA users experienced significantly lower rates of PJI (1.5% vs. 2.0%; RR 0.74; 95% CI 0.57, 0.96; P = 0.02) compared to non-users in a 2-year postoperative period. Among diabetic patients, GLP-1 RA users had significantly lower PJI rates (1.7% vs. 2.5%; RR 0.68; 95% CI 0.52, 0.89; P < 0.01). There were no significant differences between rates of revision, mechanical loosening, periprosthetic fractures, or other mechanical complications in the overall or diabetic-only cohorts.ConclusionGLP-1 RA use was associated with a reduced risk of PJI in a 2-year postoperative period without any significant differences in mechanical outcomes in both overall and diabetic-only cohorts. This laterality-verified analysis provides more accurate outcome attribution than prior database studies and supports a selective protective effect of GLP-1 RAs against infection-related rather than mechanical complications following TKA.
-
Glucagon-like peptide-1 receptor agonists and retained gastric contents on endoscopy: a prospective observational study.
AI summary of the abstract, unverified
- Prospective observational study of 256 patients undergoing elective upper endoscopy, comparing those taking GLP-1 receptor agonists with those not taking them.
- GLP-1 RA users were told to hold the drug for one week and follow a 24-hour clear liquid diet, while controls followed standard 8-hour fasting.
- Retained gastric contents occurred in 8% of GLP-1 RA users versus 6% of controls, a difference that was not statistically significant (P = 0.55), and no aspiration events occurred.
- Endoscopists more often reported concern about significant gastric contents in the GLP-1 RA group (19% vs 7%), and the authors call the study small.
Original abstract (PubMed)
PURPOSE: Retrospective evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with retained gastric contents (RGC) after standard 8-hr fasting, possibly increasing aspiration risk. The primary aim of this study was to compare the incidence of RGC on upper endoscopy after appropriate preoperative fasting in patients taking GLP-1 RAs vs patients not taking GLP-1 RAs. METHODS: We conducted prospective observational study of 256 patients scheduled for elective endoscopy involving stomach visualization. The primary outcome was RGC, defined as solid content or liquid-only content > 1.5 mL·kg-1 body weight. Control patients followed standard 8-hr fasting, while patients taking GLP-1 RAs were instructed to hold this medication 1 week prior and were limited to a preprocedural 24-hr clear liquid diet. We measured RGCvia suctioning whenever possible and recorded subjective physician impressions. Secondary outcomes included aspiration events, procedure abortion, and conversion to general anesthesia. We evaluated the differences between groups using two-sample t tests or Wilcoxon rank-sum test for continuous and ordinal variables and Chi square tests or Fisher's exact test for categorical variables. We analyzed potentially confounding variables via logistic regression. RESULTS: There was no statistically significant difference in the incidence of RGC between patients taking GLP-1 RAs (8%) vs controls (6%, P = 0.55). There were no occurrences of aspiration events, procedure abortion, or relevant conversion to general anesthesia. Endoscopy physician-reported concern of significant gastric contents was higher in the GLP-1 RA group compared with the control group (19% vs 7%). CONCLUSIONS: In this small observational study, no statistically significant increase in RGC was noted when preprocedural instructions advised patients to hold GLP-1 RAs 1 week prior to endoscopy and follow a preprocedural 24-hr clear liquid diet.
-
Preoperative fasting status and retained gastric contents in patients undergoing endoscopy who are using glucagon-like peptide type 1 receptor agonists: a multicentre retrospective study.
AI summary of the abstract, unverified
- Multicentre retrospective cohort of 337 patients on GLP-1 receptor agonists who had elective EGD at five Henry Ford Health System hospitals, 2018 to 2023.
- Preoperative solid-food fasting duration was dichotomized at the median of 15 hours and compared against retained gastric contents as reported in the endoscopy report.
- Retained gastric contents occurred in 8.4% of patients; fasting solids more than 15 hours was associated with lower odds (adjusted OR 0.33; 95% CI 0.13 to 0.81; P = 0.02).
- Liquid fasting, diabetes, GLP-1 RA duration, and suspension within 7 days were not significantly associated with retained contents, and the authors conclude that prolonged solid fasting was linked to lower odds.
Original abstract (PubMed)
PURPOSE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for the management of type 2 diabetes mellitus and obesity. Nevertheless, their known effect of delaying gastric emptying raises perioperative concerns, particularly regarding the risk of pulmonary aspiration. There is limited evidence to guide fasting practices in this population. Our aim was to evaluate the association between preoperative fasting duration and the presence of retained gastric contents (RGC) in patients receiving GLP-1 RAs who underwent esophagogastroduodenoscopy (EGD). METHODS: We conducted a multicentre retrospective cohort study involving 337 patients from five Henry Ford Health System hospitals who underwent elective EGD between January 2018 and December 2023. Eligible patients were actively taking or had recently discontinued a GLP-1 RA within 90 days prior to the procedure. The primary outcome was the presence of RGC, defined as any small, moderate, or large amount of food or gastric material explicitly reported by the endoscopist in the EGD report. For regression analyses, fasting duration for solids was dichotomized at the cohort's median value (15 hr). We performed multivariable logistic regression to evaluate the association between preoperative fasting duration, the timing of GLP-1 RA suspension, and the presence of RGC, adjusting for clinically relevant covariates. RESULTS: The overall prevalence of RGC was 8.4%. In the adjusted model, fasting from solid foods for more than 15 hr was significantly associated with lower odds of RGC (adjusted odds ratio [OR], 0.33; 95% confidence interval [CI], 0.13 to 0.81; P = 0.02). Fasting duration for liquids and presence of diabetes were not significantly associated with RGC. Suspension of GLP-1 RA within less than 7 days of the procedure related to RGC was not statistically significant (adjusted OR, 5.23; 95% CI, 0.67 to 39.38; P = 0.12). No significant association was observed between the duration of GLP-1 RA use and RGC prevalence. CONCLUSIONS: Patients with an active prescription for GLP-1 RA had lower odds of RGC during EGD after more than 15 hr fasting of solids.
-
Effect of two-week perioperative glucagon-like peptide-1 receptor agonist interruption on retained gastric contents during esophagogastroduodenoscopy: a retrospective, observational study.
AI summary of the abstract, unverified
- Single-center retrospective observational study of 15,902 elective EGD patients (August 2023 to May 2025), grouped by GLP-1RA exposure.
- Compared continued GLP-1RA use and a two-week hold against no use, with retained gastric contents as the primary outcome.
- Continued use carried higher RGC odds than no use (OR 10.68, 95% CI 3.74–30.55, p<0.001), while a two-week hold was not significantly different (OR 2.99, 95% CI 0.37–23.89, p=0.302).
- The authors conclude a two-week hold lowered RGC to a level comparable with no use, though obesity stayed higher-risk even after holding.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) slow gastric emptying and may therefore increase the risk of retained gastric contents (RGC). The optimal duration of discontinuation before esophagogastroduodenoscopy (EGD) under sedation or general anesthesia remains controversial. METHODS: We conducted a single-center, retrospective, observational study of patients who underwent elective EGD between August 2023 and May 2025. According to GLP-1RA exposure, patients were classified as (i) no GLP-1RA use, (ii) GLP-1RA continued use, or (iii) GLP-1RA two-week hold. The primary outcome was the presence of RGC, defined as any solid residue or > 100 mL of fluid visualized during EGD. Multivariate logistic regression was used to explore the relationship between GLP-1RA use and RGC. RESULTS: RGC occurred in 0.4% (63/15902) of patients with no GLP-1RA use, 5.83% (6/103) of patients with GLP-1RA continued use, and 1.61% (1/62) of patients with GLP-1RA two-week hold. GLP-1RA continued use was associated with a tenfold higher RGC risk versus no GLP-1RA use (odds ratio [OR] 10.68, 95% CI 3.74-30.55; p < 0.001), whereas a two-week hold reduced risk to a level statistically comparable with no GLP-1RA use (OR 2.99, 95% CI 0.37-23.89, p = 0.302). Obesity (BMI ≥ 28 kg/m2) independently increased RGC risk and, even after a two-week hold, yielded a tenfold higher risk of RGC versus no GLP-1RA use. Additionally, concurrent colonoscopy exerted a strong protective effect of RGC, and no RGC events occurred in patients with GLP-1RA two-week hold and concurrent colonoscopy. CONCLUSIONS: A two-week hold of GLP-1RA lowered RGC incidence to a low level comparable with no GLP-1RA use, especially in normal-weight or overweight patients and in those undergoing concurrent colonoscopy, but may be insufficient for obesity.
-
History of GLP-1 receptor agonists confer no improvement for Achilles tendon repairs: A national, propensity-matched comparison.
AI summary of the abstract, unverified
- Retrospective cohort using de-identified electronic health records from a multi-institutional network, comparing GLP-1RA users with non-users in the year before Achilles tendon repair (2015–2024).
- One-to-one propensity matching on age, sex, race, and five comorbidities produced two cohorts of 853 patients each.
- No significant differences in 1-year re-rupture (OR 1.41, 95% CI 0.70–2.81) or surgical site infection (OR 0.71, 95% CI 0.43–1.19); absolute 1-year rates among users were 1.5% and 1.7%.
- The authors conclude GLP-1RA use was not associated with improved tendon healing or lower re-rupture, and other secondary outcomes were similarly distributed.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to influence musculoskeletal repair pathways, but their clinical impact on tendon healing following Achilles tendon repair (ATR) remains unclear. PURPOSE: Although emerging evidence suggests GLP-1RAs may modulate inflammation, preserve muscle, and promote tenogenic differentiation, no large-scale study has evaluated their effect on post-ATR outcomes. STUDY DESIGN: This retrospective, cohort study analyzed a multi-institutional research network of de-identified electronic health records, identifying patients who underwent ATR between 2015 and 2024 and stratifying them based on GLP-1RA use within one year prior to surgery. METHODS: Primary outcomes included Achilles re-rupture, strain or re-injury, wound dehiscence, and surgical site infection at 90 days and 1 year postoperatively, with secondary outcomes including deep vein thrombosis, pulmonary embolism, tibial or sural neuropathy, and opioid use. One-to-one propensity score matching was performed for age, sex, race, and five comorbidities. RESULTS: Among the two matched cohorts of 853 patients each, no statistically significant differences were observed in 1-year re-rupture (OR 1.41 [0.70-2.81]) or surgical site infection (OR 0.71 [0.43-1.19]) (p > 0.01 for all comparisons), with all other outcomes similarly distributed. Absolute complication rates among GLP-1RA users aligned with established benchmarks, including a 1-year re-rupture rate of 1.5% and surgical site infection rate of 1.7%, with all outcome differences versus non-users remaining within a 5% margin. CONCLUSION: Despite their theorized regenerative benefits, GLP-1RAs were not associated with improved tendon healing or lower re-rupture rates following ATR, suggesting their use does not necessitate changes to perioperative management or risk stratification practices.
Earlier evidence / dates not confirmed
Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.
-
GLP-1 Receptor Agonists versus Bariatric Surgery: A Global Health Network Analysis of Panniculectomy Outcomes.
AI summary of the abstract, unverified
- Retrospective TriNetX database study of 24,645 panniculectomy patients from 150 organizations (2020–2025), comparing prior GLP-1 RA users (n = 6,060) with prior bariatric surgery patients (n = 4,142).
- Propensity matching on age, sex, race, HbA1c, BMI, and triglycerides was used to compare postoperative complications between the two exposure groups.
- GLP-1 RA users had lower odds of cellulitis (OR 0.62, 95% CI 0.47 to 0.83; P = 0.0015), seroma (OR 0.77, 95% CI 0.59 to 0.89; P = 0.026), and hemorrhage (OR 0.51, 95% CI 0.30 to 0.89; P = 0.016).
- The authors conclude that patients who lose weight with GLP-1 RAs may have fewer complications after panniculectomy than those who had bariatric surgery, and they note the GLP-1 RA group had higher BMI, HbA1c, and LDL.
Original abstract (PubMed)
BACKGROUND: With the increase in medically assisted weight loss, procedures such as panniculectomy are becoming more common. The surgical impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remains unclear, particularly compared with bariatric surgery. The authors compared panniculectomy outcomes and perioperative laboratory values in patients with previous GLP-1 RA use versus bariatric surgery. METHODS: The TriNetX Global Research Network was queried to identify patients who underwent panniculectomy after either GLP-1 RA use or bariatric surgery. Cohorts were formed using codes (eg, Current Procedural Terminology, International Classification of Diseases, 10th Revision) and perioperative laboratory values were compared between groups, including hemoglobin A1c (HgA1c), body mass index (BMI), low-density lipoprotein, triglycerides, and albumin. Propensity score matching for age, sex, race, HbA1c, BMI, and triglyceride levels was performed to stabilize baseline metabolic profiles and allow balanced comparison of postoperative outcomes, including cellulitis, hematoma, seroma, hemorrhage, wound dehiscence, surgical site infection, and abscess formation. RESULTS: Data from 177,467,699 patients across 150 health care organizations (2020 through 2025) were analyzed. Among all patients who underwent panniculectomy ( n = 24,645), 6060 had preoperative GLP-1 RA use and 4142 had previous bariatric surgery. GLP-1 RA users exhibited higher perioperative triglycerides, HbA1c, BMI, and low-density lipoprotein (all P < 0.05). Multivariable regression demonstrated lower odds of cellulitis (odds ratio [OR], 0.62 [95% CI, 0.47 to 0.83]; P = 0.0015), seroma (OR, 0.77 [95% CI, 0.59 to 0.89]; P = 0.026), and hemorrhage (OR, 0.51 [95% CI, 0.30 to 0.89]; P = 0.016) in the GLP-1 RA cohort. CONCLUSION: Patients who achieve weight loss with GLP-1 RAs, as opposed to bariatric surgery, may experience fewer postoperative complications after panniculectomy.
Ongoing registrations
From ClinicalTrials.govRegistrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.
No registered ongoing trials found.